U.S. market Closed. Opens in 1 day 6 hours 3 minutes

CYTO | Altamira Therapeutics Ltd. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/A305.62K63.88K174.47K-56.00K
Cost of RevenueN/A1.44M2.24MN/AN/A
Gross ProfitN/A-1.14M-2.18M174.47K-56.00K
Operating Expenses6.54M24.99M14.92M5.46M7.26M
Selling, General & Admin3.12M5.90M6.39M2.59M3.93M
Research & Development3.04M19.68M8.94M2.86M3.33M
Other Operating ExpensesN/A-586.73K-409.93KN/AN/A
Operating Income-5.92M-26.13M-17.10M-5.28M-7.26M
Other Expenses / Income-1.35M-645.64K-1.46M-2.94M433.41K
Before Tax Income-7.27M-26.54M-17.37M-8.22M-6.83M
Income Tax ExpensesN/A-10.33K21.62K-21.28K-193.84K
Net Income-7.27M-26.53M-17.39M-8.20M-6.63M
Interest ExpensesN/A911.87K189.69K135.15K28.63K
Basic Shares Outstanding491.00K45.54K33.12K15.04K14.54K
Diluted Shares Outstanding491.26K45.54K33.12K15.04K14.54K
EBITDA-1.35M-17.64M-6.72M-5.26M-7.24M
EBITDA Margin0.00%-5,770.75%-10,512.75%-3,016.55%12,930.83%
EBIT-7.27M-25.63M-17.18M-8.09M-6.80M
EBIT Margin0.00%-8,385.32%-26,891.54%-4,634.65%12,137.70%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙